Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CRISPR Therapeutics AGCRSP · Entity 3852 | Executive VP, Head of R&D | December 03, 2021 | December 08, 2021 |
| iTeos Therapeutics, Inc.ITOS · Entity 75965 | Director | June 11, 2024 | June 13, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CRISPR Therapeutics AG
Report date December 03, 2021 · Filed December 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 52,364 |
Ending reported balance
After 2021-12-06 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2021-12-03 · Exercise / conversion · Acquired 26,667 · Balance 64,971 F1: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. F2: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Row 2 · 2021-12-06 · Tax withholding · Disposed 12,607 · Balance 52,364 F3: On December 3, 2019, the reporting person was granted 40,000 restricted stock units. On December 3, 2021, 26,667 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 13,333 |
Reported balance
After 2021-12-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-12-03 · Exercise / conversion · Acquired 26,667 · Balance 13,333 F2: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022.
F2: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares.
F3: On December 3, 2019, the reporting person was granted 40,000 restricted stock units. On December 3, 2021, 26,667 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person.
iTeos Therapeutics, Inc.
Report date June 11, 2024 · Filed June 13, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.32 · Expires 2034-06-11 | Direct | 24,200 |
Reported balance
After 2024-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-11 · Grant · Acquired 24,200 · Balance 24,200 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 11, 2024 Filed Jun 13, 2024 20:00 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | GrantStock Option (Right to Buy) · Derivative | 24,200 | $0.00 Strike: $16.32 | $0.00 |
DisclosureSEC source: 0000950170-24-073258 · ownership.xml · derivative · entry 1 Ho Tony W · CIK 0001713637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,200 Underlying: Common Stock · 24,200 shares Expires 2034-06-11 Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 19:55 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | GrantStock Option (Right to Buy) · Derivative | 22,383 | $0.00 Strike: $14.77 | $0.00 |
DisclosureSEC source: 0001209191-23-037592 · doc4.xml · derivative · entry 1 Ho Tony W · CIK 0001713637 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,383 Underlying: Common Stock · 22,383 shares Expires 2033-06-13 Read SEC document |
| June 09, 2022 Filed Jun 10, 2022 19:52 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | GrantStock Option (Right to Buy) · Derivative | 17,538 | $0.00 Strike: $18.78 | $0.00 |
DisclosureSEC source: 0001209191-22-036138 · doc4.xml · derivative · entry 1 Ho Tony W · CIK 0001713637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,538 Underlying: Common Stock · 17,538 shares Expires 2032-06-09 F1 · derivative.exercise_date: This stock option will vest and become exercisable in full upon the earlier to occur of (a) June 9, 2023 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| December 06, 2021 Filed Dec 8, 2021 01:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Tax withholdingCommon Shares | 12,607 | $69.17 | $872,026.19 |
DisclosureSEC source: 0001209191-21-068454 · doc4.xml · nonDerivative · entry 2 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,364 F3 · kind: On December 3, 2019, the reporting person was granted 40,000 restricted stock units. On December 3, 2021, 26,667 restricted stock units vested. Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| December 03, 2021 Filed Dec 8, 2021 01:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 26,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-068454 · doc4.xml · derivative · entry 3 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,333 Underlying: Common Shares · 26,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F1 · derivative.exercise_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. F1 · derivative.expiration_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. Read SEC document |
| December 03, 2021 Filed Dec 8, 2021 01:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 26,667 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-068454 · doc4.xml · nonDerivative · entry 1 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,971 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| October 15, 2021 Filed Oct 19, 2021 00:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 13,800 | $0.00 Strike: $97.00 | $0.00 |
DisclosureSEC source: 0001209191-21-060774 · doc4.xml · derivative · entry 1 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,800 Underlying: Common Shares · 13,800 shares Expires 2031-10-15 F1 · derivative.exercise_date: This option was granted on October 15, 2021 with respect to 13,800 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 15, 2021. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:21 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | GrantStock Option (Right to Buy) · Derivative | 4,560 | $0.00 Strike: $26.03 | $0.00 |
DisclosureSEC source: 0000899243-21-025136 · doc4.xml · derivative · entry 1 Ho Tony W · CIK 0001713637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,560 Underlying: Common Stock · 4,560 shares Expires 2031-06-17 F1 · derivative.exercise_date: This stock option shall vest and become exercisable in full upon the earlier to occur of (a) June 17, 2022 or (b) the next annual meeting of the Issuer's stockholders. Read SEC document |
| April 29, 2021 Filed May 3, 2021 19:01 UTC | iTeos Therapeutics, Inc. ITOS · Entity 75965 | GrantStock Option (Right to Buy) · Derivative | 33,217 | $0.00 Strike: $24.11 | $0.00 |
DisclosureSEC source: 0000899243-21-017837 · doc4.xml · derivative · entry 1 Ho Tony W · CIK 0001713637 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,217 shares Expires 2031-04-29 F1 · derivative.exercise_date: This stock option shall vest over 3 years, with 1/3 vesting on April 29, 2022, and thereafter in equal monthly installments over the next 24 months subject to the Reporting Person's continued service as a director through the applicable vesting date. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 22:41 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-020250 · doc4.xml · derivative · entry 4 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Shares · 9,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F5 · derivative.exercise_date: This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025. F5 · derivative.expiration_date: This restricted stock unit award was granted on March 11, 2021 with respect to 9,000 Common Shares, with (i) one quarter of the shares vesting on March 11, 2022, (ii) one quarter of the shares vesting on March 11, 2023, (iii) one quarter of the shares vesting on March 11, 2024, and (iv) one quarter of the shares vesting on March 11, 2025. Read SEC document |
| March 11, 2021 Filed Mar 12, 2021 22:41 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 23,334 | $0.00 Strike: $133.88 | $0.00 |
DisclosureSEC source: 0001209191-21-020250 · doc4.xml · derivative · entry 3 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,334 Underlying: Common Shares · 23,334 shares Expires 2031-03-11 F4 · derivative.exercise_date: This option was granted on March 11, 2021 with respect to 23,334 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 11, 2021. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 22:41 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Tax withholdingCommon Shares | 2,141 | $124.15 | $265,805.15 |
DisclosureSEC source: 0001209191-21-020250 · doc4.xml · nonDerivative · entry 2 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,304 F3 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 10, 2021 Filed Mar 12, 2021 22:41 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 4,583 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-020250 · doc4.xml · nonDerivative · entry 1 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,445 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This restricted stock unit award was granted on March 10, 2020 with respect to 13,750 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 22:40 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Tax withholdingCommon Shares | 1,585 | $114.65 | $181,720.25 |
DisclosureSEC source: 0001209191-21-019157 · doc4.xml · nonDerivative · entry 2 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,862 F4 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 05, 2021 Filed Mar 9, 2021 22:40 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 3,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-019157 · doc4.xml · nonDerivative · entry 1 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,447 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On March 5, 2019, the reporting person was granted 10,000 restricted stock units. On March 5, 2021, 3,333 restricted stock units vested. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · balance_after: Includes 150 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 21:55 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionStock Option (right to buy) · Derivative | 23,551 | $0.00 Strike: $16.90 | $0.00 |
DisclosureSEC source: 0001209191-20-064857 · doc4.xml · derivative · entry 11 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 236,449 Underlying: Common Shares · 23,551 shares Expires 2027-08-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F12 · derivative.exercise_date: This option was granted on August 1, 2017 with respect to 260,000 Common Shares of which 25% vested on 8/1/2018 and the remaining 75% vest in 36 equal monthly installments on the final day of each succeeding calendar month. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 21:55 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 2,951 | $150.61 | $444,450.11 |
DisclosureSEC source: 0001209191-20-064857 · doc4.xml · nonDerivative · entry 10 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,964 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.44 to $151.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 21:55 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 5,000 | $149.73 | $748,650.00 |
DisclosureSEC source: 0001209191-20-064857 · doc4.xml · nonDerivative · entry 9 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,915 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.20 to $150.195, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 21:55 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 8,400 | $148.38 | $1,246,392.00 |
DisclosureSEC source: 0001209191-20-064857 · doc4.xml · nonDerivative · entry 8 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,915 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.19 to $149.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 21:55 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,400 | $147.05 | $205,870.00 |
DisclosureSEC source: 0001209191-20-064857 · doc4.xml · nonDerivative · entry 7 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,315 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.00 to $147.125, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 21:55 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 500 | $152.41 | $76,205.00 |
DisclosureSEC source: 0001209191-20-064857 · doc4.xml · nonDerivative · entry 6 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,715 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $152.04 to $152.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 21:55 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,100 | $151.58 | $166,738.00 |
DisclosureSEC source: 0001209191-20-064857 · doc4.xml · nonDerivative · entry 5 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,215 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $151.00 to $151.97, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 21:55 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,600 | $150.16 | $240,256.00 |
DisclosureSEC source: 0001209191-20-064857 · doc4.xml · nonDerivative · entry 4 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,315 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $149.755 to $150.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 21:55 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 900 | $149.18 | $134,262.00 |
DisclosureSEC source: 0001209191-20-064857 · doc4.xml · nonDerivative · entry 3 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,915 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $148.69 to $149.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 21:55 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 1,700 | $148.11 | $251,787.00 |
DisclosureSEC source: 0001209191-20-064857 · doc4.xml · nonDerivative · entry 2 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,815 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $147.44 to $148.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| December 21, 2020 Filed Dec 22, 2020 21:55 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 23,551 | $16.90 | $398,011.90 |
DisclosureSEC source: 0001209191-20-064857 · doc4.xml · nonDerivative · entry 1 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,515 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 217 shares acquired under the CRISPR Therapeutics AG 2016 Employee Stock Purchase Plan. Read SEC document |
| October 05, 2020 Filed Oct 6, 2020 21:32 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 16,666 | $0.00 Strike: $86.75 | $0.00 |
DisclosureSEC source: 0001209191-20-054055 · doc4.xml · derivative · entry 1 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,666 Underlying: Common Shares · 16,666 shares Expires 2030-10-05 F1 · derivative.exercise_date: This option was granted on October 5, 2020 with respect to 16,666 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of November 5, 2020. Read SEC document |
| June 23, 2020 Filed Jun 24, 2020 21:58 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 6,929 | $75.20 | $521,060.80 |
DisclosureSEC source: 0001209191-20-038761 · doc4.xml · nonDerivative · entry 2 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,747 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.00 to $75.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 22, 2020 Filed Jun 24, 2020 21:58 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 229 | $70.14 | $16,062.06 |
DisclosureSEC source: 0001209191-20-038761 · doc4.xml · nonDerivative · entry 1 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,676 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 26, 2020 Filed May 27, 2020 20:32 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 6,100 | $70.14 | $427,854.00 |
DisclosureSEC source: 0001209191-20-032312 · doc4.xml · nonDerivative · entry 2 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,905 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.59, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 22, 2020 Filed May 27, 2020 20:32 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | SaleCommon Shares | 600 | $70.05 | $42,030.00 |
DisclosureSEC source: 0001209191-20-032312 · doc4.xml · nonDerivative · entry 1 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,005 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.07, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:20 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 13,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-018491 · doc4.xml · derivative · entry 2 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,750 Underlying: Common Shares · 13,750 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F3 · derivative.exercise_date: This restricted stock unit award was granted on March 10, 2020 with respect to 13,750 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023. F3 · derivative.expiration_date: This restricted stock unit award was granted on March 10, 2020 with respect to 13,750 Common Shares, with (i) one third of the shares vesting on March 10, 2021, (ii) one third of the shares vesting on March 10, 2022, and (iii) one third of the shares vesting on March 10, 2023. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 20:20 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $44.67 | $0.00 |
DisclosureSEC source: 0001209191-20-018491 · doc4.xml · derivative · entry 1 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Shares · 55,000 shares Expires 2030-03-10 F1 · derivative.exercise_date: This option was granted on March 10, 2020 with respect to 55,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 10, 2020. Read SEC document |
| March 06, 2020 Filed Mar 9, 2020 20:13 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Tax withholdingCommon Shares | 1,563 | $52.64 | $82,276.32 |
DisclosureSEC source: 0001209191-20-017240 · doc4.xml · nonDerivative · entry 2 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,605 F3 · shares: Amount reported represents the number of shares required to be sold by the reporting person to cover the tax withholding obligation in connection with the vesting of these restricted stock units. This sale is mandated by the Company's RSU Settlement Policy to fund the tax withholding obligation and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 05, 2020 Filed Mar 9, 2020 20:13 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 3,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-017240 · doc4.xml · nonDerivative · entry 1 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,168 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On March 5, 2019, the reporting person was granted 10,000 restricted stock units. On March 5, 2020, 3,333 restricted stock units vested. F2 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:00 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-059277 · doc4.xml · derivative · entry 1 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Shares · 40,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022 F2 · derivative.expiration_date: The restricted stock units shall vest as follows: two-thirds of the grant shall vest on December 3, 2021 and the remaining one-third shall vest on December 3, 2022 Read SEC document |
| August 02, 2019 Filed Aug 5, 2019 21:49 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Tax withholdingCommon Shares | 14,534 | $52.56 | $763,907.04 |
DisclosureSEC source: 0001209191-19-044652 · doc4.xml · nonDerivative · entry 2 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,835 Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 21:49 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-044652 · doc4.xml · derivative · entry 3 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 37,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: On August 1, 2017, the reporting person was granted 75,000 restricted stock units that vested in two equal annual installments on 8/1/2018 and 8/1/2019. F2 · derivative.expiration_date: On August 1, 2017, the reporting person was granted 75,000 restricted stock units that vested in two equal annual installments on 8/1/2018 and 8/1/2019. Read SEC document |
| August 01, 2019 Filed Aug 5, 2019 21:49 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 37,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-044652 · doc4.xml · nonDerivative · entry 1 Ho Tony W · CIK 0001713637 · Executive VP, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,369 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 21:12 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $40.87 | $0.00 |
DisclosureSEC source: 0000899243-19-006649 · doc4.xml · derivative · entry 2 Ho Tony W · CIK 0001713637 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2029-03-05 F2 · derivative.exercise_date: This option was granted on March 5, 2019 with respect to 75,000 Common Shares. 100% of the shares will vest in 48 equal monthly installments, with the first vesting date of April 5, 2019. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 21:12 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units | 10,000 | $40.87 | $408,700.00 |
DisclosureSEC source: 0000899243-19-006649 · doc4.xml · nonDerivative · entry 1 Ho Tony W · CIK 0001713637 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,869 F1 · shares: This restricted stock unit award was granted on March 5, 2019 with respect to 10,000 Common Shares, with (i) 3,333 shares vesting on March 5, 2020, (ii) 3,333 shares vesting on March 5, 2021, and (iii) 3,334 shares vesting on March 5, 2022. Each restricted stock unit represents a contingent right to receive one CRSP Common Share. Read SEC document |
| August 02, 2018 Filed Aug 3, 2018 21:43 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Tax withholdingCommon Shares | 14,631 | $48.43 | $708,579.33 |
DisclosureSEC source: 0000899243-18-021415 · doc4.xml · nonDerivative · entry 2 Ho Tony W · CIK 0001713637 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,869 Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 21:43 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionRestricted Stock Units · Derivative | 37,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-18-021415 · doc4.xml · derivative · entry 3 Ho Tony W · CIK 0001713637 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Shares · 37,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: On August 1, 2017, the reporting person was granted 75,000 restricted stock units that vest in two equal annual installments on 8/1/2018 and 8/1/2019. F2 · derivative.expiration_date: On August 1, 2017, the reporting person was granted 75,000 restricted stock units that vest in two equal annual installments on 8/1/2018 and 8/1/2019. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 21:43 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | Exercise / conversionCommon Shares | 37,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-021415 · doc4.xml · nonDerivative · entry 1 Ho Tony W · CIK 0001713637 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. Read SEC document |
| June 15, 2018 Filed Jun 16, 2018 01:38 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 43,000 | $0.00 Strike: $59.31 | $0.00 |
DisclosureSEC source: 0000899243-18-016875 · doc4.xml · derivative · entry 1 Ho Tony W · CIK 0001713637 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Shares · 43,000 shares Expires 2028-06-15 F1 · derivative.exercise_date: This option was granted on June 15, 2018 with respect to 43,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 21:54 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Option (Right to Buy) · Derivative | 53,000 | $0.00 Strike: $51.49 | $0.00 |
DisclosureSEC source: 0000899243-18-006957 · doc4.xml · derivative · entry 1 Ho Tony W · CIK 0001713637 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,000 Underlying: Common Shares · 53,000 shares Expires 2028-03-07 F1 · derivative.exercise_date: This option was granted on March 7, 2018 and shall vest in 48 equal monthly installments. Read SEC document |
| August 01, 2017 Filed Aug 2, 2017 20:30 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantStock Options (Right to Buy) · Derivative | 260,000 | $0.00 Strike: $16.90 | $0.00 |
DisclosureSEC source: 0000899243-17-019539 · doc4.xml · derivative · entry 2 Ho Tony W · CIK 0001713637 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,000 Underlying: Common Shares · 260,000 shares Expires 2027-08-01 F3 · derivative.exercise_date: This option was granted on August 1, 2017 with respect to 260,000 Common Shares of which 25% shall vest on 8/1/2018 and the remaining 75% shall vest in 36 equal monthly installments on the final day of each succeeding calendar month. Read SEC document |
| August 01, 2017 Filed Aug 2, 2017 20:30 UTC | CRISPR Therapeutics AG CRSP · Entity 3852 | GrantRestricted Stock Units · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-019539 · doc4.xml · derivative · entry 1 Ho Tony W · CIK 0001713637 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of CRSP Common Shares. F2 · derivative.exercise_date: The restricted stock units vest in two equal annual installments on 8/1/2018 and 8/1/2019. F2 · derivative.expiration_date: The restricted stock units vest in two equal annual installments on 8/1/2018 and 8/1/2019. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.